You are here

lymphoma

Roche trumpets new glofitamab data in lymphoma at ASCO

Pharmaforum

Fri, 05/27/22 - 10:24 am

bispecific antibodies

CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise

BioSpace

Thu, 05/12/22 - 10:42 pm

CRISPR Therapeutics

clinical trials

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

Pharmaforum

Mon, 04/4/22 - 10:18 am

Gilead Sciences

Bristol Myers Squibb

large B-cell lymphoma

'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update

Fierce Pharma

Wed, 02/23/22 - 10:09 pm

Bristol Myers Squibb

Biogen buys into fast-advancing Roche cancer drug

BioPharma Dive

Tue, 02/1/22 - 11:30 pm

ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma

Fierce Pharma

Sat, 12/11/21 - 09:22 pm

Gilead Sciences

Bristol Myers Squibb

What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More

OBR Oncology

Wed, 11/24/21 - 10:23 am

Affimed spurs promising response numbers in NK cell study, but durability will be the big question

Endpoints

Mon, 11/22/21 - 10:33 am

natural killer cell therapy

Allogene cell therapy trials halted by FDA after safety finding

BioPharma Dive

Thu, 10/7/21 - 09:43 pm

Allogene Therapeutics

clinical trials

Roche sets bar in early lymphoma treatment with Polivy study results

BioPharma Dive

Tue, 08/10/21 - 11:23 pm

Regeneron resumes enrollment in lymphoma drug trials

Reuters

Mon, 05/17/21 - 11:05 pm

clinical trials

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Fierce Pharma

Sun, 03/7/21 - 01:29 pm

Bristol Myers Squibb

New study points to why CAR-T therapy may fail in some lymphoma patients

Fierce Biotech

Thu, 02/4/21 - 08:05 pm

FDA to decide on TG Therapeutics’ lymphoma drug early next year

Pharmaforum

Thu, 08/13/20 - 11:53 pm

TG Therapeutics

Bristol-Myers Squibb

Scopus Bio preps trials of gene-silencing immuno-oncology drug

Pharmaforum

Fri, 06/12/20 - 10:56 am

Scopus BioPharma

immuno-oncology

ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma

Fierce Biotech

Fri, 05/29/20 - 10:57 am

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

Xconomy

Mon, 01/13/20 - 11:51 pm

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

Pharmaceutical Business Review

Tue, 10/1/19 - 10:50 pm

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Yahoo/Reuters

Tue, 07/30/19 - 07:51 am

TG aims for accelerated approval of lymphoma candidate

BioCentury

Fri, 03/1/19 - 09:37 am

TG Therapeutics

Pages